Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

35

Revenue 2017

Symbicort

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Symbicort was produced by AstraZeneca and Astellas.

GSK's triple COPD therapy tops Symbicort in phase III trial

GSK's triple COPD therapy tops Symbicort in phase III trial GlaxoSmithKline has continued to build the case for its three-drug combination for chronic obstructive pulmonary disease, saying it outperformed AstraZeneca's Symbicort in a head-to-head study. ... The phase III FULFIL trial compared the once-daily

AstraZeneca sets sights on China with Takeda deal

AstraZeneca sets sights on China with Takeda deal AZ's respiratory franchise is currently headed by asthma and chronic obstructive pulmonary disease (COPD) drug Symbicort (budesonide and formoterol), which made $2.5bn in the first nine months of the

Humira remains top pharma product, but Sovaldi closes in

Humira remains top pharma product, but Sovaldi closes in 2014. . Sales were $6.7bn for the year - a fall of 20% as pricing pressures and competition from products such as AstraZeneca's Symbicort affected its once dominant market share.

Prescribing costs jump in England

Prescribing costs jump in England After Seretide, another respiratory drug from AstraZeneca - Symbicort - saw the second highest spend with £89m, while Novo Nordisk's insulin NovoRapid came in third with the NHS spending £75m on the

AstraZeneca and EHR firm to use drug alert system

AstraZeneca and EHR firm to use drug alert system AZ currently markets a number of blockbuster medicines for respiratory disorders, including its new treatment Duaklir Genuair, as well as Pulmicort and Symbicort.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics